| 價格 | ¥179 | ¥359 | ¥653 |
| 包裝 | 10mg | 25mg | 50mg |
| 最小起訂量 | 10mg |
| 發(fā)貨地 | 上海 |
| 更新日期 | 2026-06-29 |
| 中文名稱:氯谷胺 | 英文名稱:Loxiglumide |
| CAS:107097-80-3 | 品牌: TargetMol |
| 產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 純度規(guī)格: 99.81% | 產(chǎn)品類別: 抑制劑 |
| 貨號: T001|T2312 |
| 名稱 | Loxiglumide |
| 描述 | Loxiglumide (CR-1505) is an antagonist of cholecystokinin (CCK-1) receptor. |
| 激酶實(shí)驗(yàn) | Kinase binding assays: For optimization of Axl/TAM receptor inhibitors, an Axl binding assay is established (HTRF method; Kinase tracer 236). This assay is based on the binding and displacement of the Alexa Fluor 647-labelled Kinase tracer 236 to each glutathione S-transferase (GST)-tagged kinase used in the binding assay. Binding of the tracer to the kinase was detected by using europium (Eu)-labelled anti-GST antibodies. Simultaneous binding of both the fluorescent tracer and the Eu-labelled antibodies to the GST-tagged kinase generates a fluorescence resonance energy transfer (FRET) signal. Binding of inhibitor to the kinase competes for binding with the tracer, resulting in a loss of the FRET signal. For the assay, the compound is diluted in 20?mM HEPES, pH?8.0, 1?mM DTT, 10?mM MgCl2 and 0.01% Brij35. Then, the kinase of interest (5?nM final concentration), fluorescent tracer (15?nM final concentration) and LanthaScreen Eu-anti-GST antibody (2?nM final concentration) are mixed with the respective compound dilutions (from 5?nM to 10?μM) and incubated for 1?h. The FRET signal is quantified using an EnVision Multilabellreader 2104. |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | DMSO : 4.62 mg/mL (10.01 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.17 mM), Sonication is recommended. |
| 關(guān)鍵字 | Loxiglumide | Inhibitor | inhibit | CR1505 | CR 1505 | Cholecystokinin Receptor | Cholecystokinin | CCK Receptor | CCK |
| 相關(guān)產(chǎn)品 | N-Cbz-DL-tryptophan | GV150013 | GV-150013X | CCKBR agonist-2 | Spiroglumide | Itriglumide | A-65186 | Caerulein, desulfated | PHA-767491 | (Iso)-FK-480 | Lintitript | Pranazepide |
| 相關(guān)庫 | 抑制劑庫 | 抗癌活性化合物庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | ReFRAME 相關(guān)化合物庫 | 抗胰腺癌化合物庫 | NO PAINS 化合物庫 | GPCR靶點(diǎn)分子庫 | 膜蛋白靶向化合物庫 | 免疫/炎癥分子化合物庫 | 藥物功能重定位化合物庫 | 疼痛相關(guān)化合物庫 |
| 成立日期 | 2013-04-18 (14年) | 注冊資本 | 566.265100萬人民幣 |
| 員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
| 主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
|---|---|---|---|---|
| 詢價 |
VIP1年
|
吉林省吉創(chuàng)致遠(yuǎn)醫(yī)藥有限公司
|
2026-07-23 | |
| 詢價 |
VIP4年
|
山東迪貝克生物工程有限公司
|
2026-07-27 | |
| 詢價 |
VIP8年
|
成都彼樣生物科技有限公司
|
2026-07-27 | |
| ¥322.90 |
VIP3年
|
上海阿拉丁生化科技股份有限公司
|
2026-06-10 |